Solventum Corporation (NYSE:SOLV – Get Free Report) shares crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $87.84 and traded as high as $90.61. Solventum shares last traded at $89.1450, with a volume of 2,167,940 shares.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on SOLV shares. KeyCorp lifted their price target on shares of Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. BMO Capital Markets started coverage on Solventum in a report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price target on the stock. Piper Sandler raised their price objective on Solventum from $92.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Stifel Nicolaus lifted their price objective on Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Wedbush boosted their target price on Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Ten investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.55.
Check Out Our Latest Stock Analysis on Solventum
Solventum Price Performance
The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02. The stock has a market capitalization of $15.17 billion, a PE ratio of 10.90, a P/E/G ratio of 1.24 and a beta of 0.69. The company’s fifty day simple moving average is $87.84 and its two-hundred day simple moving average is $78.60.
Solventum (NYSE:SOLV – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.64. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. During the same quarter in the prior year, the firm earned $1.69 earnings per share. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. As a group, sell-side analysts predict that Solventum Corporation will post 7.21 EPS for the current year.
Institutional Investors Weigh In On Solventum
Institutional investors and hedge funds have recently bought and sold shares of the stock. Laurel Wealth Advisors LLC purchased a new stake in shares of Solventum during the 3rd quarter valued at $29,000. Clearstead Trust LLC increased its holdings in shares of Solventum by 61.0% during the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock worth $26,000 after buying an additional 150 shares during the last quarter. JNBA Financial Advisors increased its holdings in shares of Solventum by 71.9% during the 2nd quarter. JNBA Financial Advisors now owns 507 shares of the company’s stock worth $39,000 after buying an additional 212 shares during the last quarter. Ameritas Advisory Services LLC purchased a new position in shares of Solventum in the 2nd quarter worth $47,000. Finally, Ancora Advisors LLC purchased a new position in shares of Solventum in the 2nd quarter worth $56,000.
About Solventum
Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.
The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.
Read More
- Five stocks we like better than Solventum
- Keurig Dr Pepper’s Beverage Growth Raises a Tough Question About Its Coffee Split
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
